The tetrapeptide AcSDKP reduces the sensitivity of murine CFU-MK and CFU-GM progenitors to aracytine in vitro and in vivo

International Journal of Hematology

Volumn 68, Issue 2, 1998, Pages 145-155

  Aidoudi, Sallouha ^a   Guigon, Martine ^b   Drouet, Valerie ^a   Caen, Jacques P ^a   Chao Han, Zhong ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

AcSDKP; Ara c; Haemoprotection; Megakaryocytopoiesis; Progenitors

Indexed keywords

CYTARABINE; CYTOSTATIC AGENT; SERASPENIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CELL SURVIVAL; CELL VIABILITY; COLONY FORMING UNIT GM; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG EFFECT; MALE; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031787648     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(98)00048-6     Document Type: Article

References (24)

1. Chabner BA, Myers CE. Antitumor Antibiotics. DeVita J.R., Hellman S., Rosenberg S.A. Cancer, Principles and Practice of Oncology. 1993;374-384 Lippincott, Philadelphia.
2. Broxmeyer HE Suppressor cytokines and regulation of myelopoiesis: biological and possible clinical uses. Am J Ped Hematol Oncol. 14:1992;22-30.
3. Moore MAS Clinical implications of positive and negative hematopoietic stem cell regulators. Blood. 78:1991;1-19.
4. Whetton A The biology and clinical potential of growth factors that regulate myeloid cell production. TiPS. 11:1990;285-289.
5. Hornung R, Longo D Hematopoietic stem cell depletion by restorative growth factor regimen during repeated high dose cyclophosphamide therapy. Blood. 80:1992;77-83.
6. Aidoudi S, Guigon M, Lebeurrier I, Caen J.P., Han Z In vivo effect of platelet factor 4 (PF4) and tetrapeptide AcSDKP on haemopoiesis of mice treated with 5-Fluouracil. Br J Haematol. 94:1996;443-448.
7. Carde P, Mathieu-Tubiana N, Vuillemin E, Delwail V, Corbion O, Deschamps-de-Paillette E Phase I-II trial of seraspenide (AcSDKP): a suppressor of myelopoiesis protects against chemotherapy myelotoxicity. Guigon M., Lemoine F.M., Dainiak N., Schecter A., Najam A. The Negative Regulation of Hematopoiesis: From Fundamental Aspects to Clinical Applications. 1993;459 John Libbey Eurotext, Paris, France.
8. Dunlop DJ, Wright EG, Lorimore S, Graham GJ, Holyoake T et al. Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1a in vivo. Blood. 79:1992;2221-2225.
9. Grzegorzewski K, Ruscett IF, Usui N, Damia G, Longo DL, Carlino JA et al. Recombinant transforming growth factor β1 and β2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. J Exp Med. 180:1995;1047-1057.
10. Han ZC, Lu M, Defart M, Boval B, Schlegel N, Caen JP Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic progenitor cells from maternal peripheral blood. Blood. 89:1997;2328-2335.
11. Paukovits WR, Moser MH, Binder KA, Paukovits J Protection from arabinofuranosylcytosine and N-mustard-induced myelotoxicity using hemoregulatory peptide. Blood. 50:1991;1313-1323.
12. Frindel E, Guigon M Inhibition of CFU entry into cycle by a bone marrow extract. Exp Hematol. 5:1977;74-76.
13. Lenfant M, Wdzieczak-Bakala J, Guittet E, Promé JC, Sotty D, Frindel E Inhibitor of hematopoietic pluripotent stem cell proliferation:purification and determination of its structure. Proc Natl Acad Sci USA. 86:1989;779-782.
14. Guigon M, Frindel E Inhibition of CFU-S entry into cell cycle after irradiation and drug treatment. Biomedicine. 29:1978;176-178.
15. Guigon M, Mary JY, Enouf J, Frindel E Protection of mice against lethal doses of 1-b-arabinofuranosyl-cytosine by pluripotent stem cell inhibitors. Cancer Res. 42:1982;638-642.
16. Bogden AE, Carde P, Deschamps de Paillette E, Moreau JP, Tubiana M, Frindel E Amelioration of chemotherapy induced toxicity by cotreatment with a hematopoiesis-inhibiting tetrapeptide AcSDKP. Ann NY Acad Sci. 628:1991;126-139.
17. Ramirez L, Munck J, Ardouin P, Bayle C, Deschamps de Paillette E, Carde P Effets protecteurs hématopoïétiques de l'AcSDKP (BIM 32001) contre les effects cytotoxiques de l'Ara-C sur la souris. Bull Cancer. 79:1992;620.
18. Han ZC, Bellucci S, Wan HY, Caen JP New insights into the regulation of megakaryocytopoiesis by haematopoietic and fibroblastic growth factors and transforming growth factor β1. Br J Haematol. 81:1992;1-5.
19. Jackson CW Cholinesterase as a possible marker of a early cells of the megakaryocyte. Blood. 42:1973;413-421.
20. Sargent JM, Taylor CG Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukemia. Br J Cancer. 60:1989;206-210.
21. Guigon M, Bonnet D, Lemoine F et al. Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP. Exp Hematol. 18:1990;1112-1115.
22. Bonnet D, Lemoine FM, Pontvert-Delucq S, Baillou C, Najman A, Guigon M Direct and reversible inhibitory effect of the tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (Seraspenide) on the growth of Human CD34+subpopulations in response to growth factors. Blood. 82:1993;3307-3314.
23. Wierenga P, Konings A Goralatide (AcSDKP) selectively protects murine hematopoietic progenitors and stem cells against hyperthermic damage. Exp Hematol. 24:1996;246-252.
24. Masse A, Ramirez LH, Bindoula G et al. The tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitors. Blood. 91:1998;441-449.